XB130 is overexpressed in prostate cancer and involved in cell growth and invasion

Abstract

// Bin Chen 1, 2, * , Mengying Liao 3, * , Qiang Wei 4, * , Feiye Liu 5 , Qinsong Zeng 6 , Wei Wang 6 , Jun Liu 6 , Jianing Hou 7 , Xinpei Yu 8, 9 , Jian Liu 9 1 Department of Science and Training, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China 2 Guangzhou Huabo Biopharmaceutical Research Institute, Guangzhou, Guangdong, China 3 Department Of Pathology, Peking University Shenzhen Hospital, Shenzhen, China 4 Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China 5 Cancer Center, Traditional Chinese Medicine-Integrated Hospital of Southern Medical University, Guangzhou, Guangdong, China 6 Department of Urology, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China 7 Sun Yat-Sen University, Guangzhou, China 8 Guangdong Provincial Key Laboratory of Geriatric Infection and Organ Function Support and Guangzhou Key Laboratory of Geriatric Infection and Organ Function Support, Guangzhou, Guangdong, China 9 Center for Geriatrics, General Hospital of Guangzhou Military Command of People’s Liberation Army, Guangzhou, Guangdong, China * These authors contributed equally to this work Correspondence to: Xinpei Yu, email: yxinpei@126.com Jian Liu, email: liujgzzyy@126.com Keywords: XB130, adaptor protein, proliferation, invasion, Akt Received: January 27, 2016      Accepted: June 29, 2016      Published: August 05, 2016 ABSTRACT XB130 is a cytosolic adaptor protein involved in various physiological processes and oncogenesis of certain malignancies, but its role in the development of prostate cancer remains unclear. In current study, we examined XB130 expression in prostate cancer tissues and found that XB130 expression was remarkably increased in prostate cancer tissues and significantly correlated with increased prostate specific antigen (PSA), free PSA (f-PSA), prostatic acid phosphatase (PAP) and T classification. Patients with highly expressed XB130 had significantly decreased survival, which suggested XB130 as a possible prognostic indicator for prostate cancer. In vitro experiments showed that reduced XB130 expression restrained tumor growth both in vitro and in vivo . Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. Results from transwell assay demonstrated that downregulation of XB130 may attenuate invasion and metastasis of prostate cancer. Semiquantitative analysis of Western blot suggested that decreased XB130 expression was accompanied by diminished Akt signaling and EMT process. Thus, above observations suggest that XB130 may be a novel molecular marker and potent therapeutic target for prostate cancer.